Over 1.3 billion U.S. dollars to develop a new generation of bispecific antibody therapy Janssen reached cooperation

On October 20, 2021, F-star Therapeutics announced that it has reached a licensing and cooperation agreement with Janssen Biotech, a subsidiary of Johnson & Johnson

F-star's Fcab platform can transform the Fc region of natural antibodies to introduce two additional different antigen binding sites

▲The Fcab platform can add 2 antigen binding sites in the Fc region of natural antibodies (picture source: F-star official website)

mAb2 works through 3 mechanisms:

1) Crosslinking: Bring together two different cells, or two receptors on the same cell, to activate the immune system

2) Clustering: clustering receptors on the cell surface to activate key immune cell pathways

3) Conditionality: Prevent immune cells from being activated by healthy cells

▲Three mechanisms of action of the quadrivalent bispecific antibody mAb2 (picture source: F-star official website)

According to the terms of the agreement, F-star is entitled to an upfront payment of US$17.

Reference materials:

[1] F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics.

(The original text has been deleted)